197 related articles for article (PubMed ID: 12972702)
1. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
2. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
[TBL] [Abstract][Full Text] [Related]
3. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
4. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
Harjunpää A; Wiklund T; Collan J; Janes R; Rosenberg J; Lee D; Grillo-López A; Meri S
Leuk Lymphoma; 2001 Aug; 42(4):731-8. PubMed ID: 11697503
[TBL] [Abstract][Full Text] [Related]
6. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
8. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
9. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
[TBL] [Abstract][Full Text] [Related]
11. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
Kikuchi A; Kawada H; Iwaki Y; Machida S; Tsuchiya T; Fukuda R; Hotta T
Rinsho Ketsueki; 2004 Dec; 45(12):1255-7. PubMed ID: 15678918
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
[TBL] [Abstract][Full Text] [Related]
13. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
14. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
Cook RC; Connors JM; Gascoyne RD; Fradet G; Levy RD
Lancet; 1999 Nov; 354(9191):1698-9. PubMed ID: 10568575
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
16. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
17. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
19. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
Siegal T
J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]